 Connection
Jeffrey Bennett to Complement Inactivating Agents
This is a "connection" page, showing publications Jeffrey Bennett has written about Complement Inactivating Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.140 |
|
|
|
-
Given KS, Acker EG, Macklin WB, Carlin D, Owens GP, Bennett JL. Complement inhibition rapidly blocks lesion extension and facilitates remyelination in neuromyelitis optica. Acta Neuropathol Commun. 2025 06 12; 13(1):129.
Score: 0.866
-
Rommer PS, Jiang W, Nolte JP, Mikami T, De Seze J, Sánchez P, Harel A, Alkabie S, Kaneko K, Bilodeau PA, Misu T, Kremer L, Bigaut K, Leypoldt F, Aktas O, Ringelstein M, Siffrin V, Zhang LJ, Cong H, Lowe M, Barreras P, Chen H, Piquet AL, Sotirchos ES, Kammeyer R, Zook J, Bennett JL, Berger T, Fujihara K, Levy M, Shi FD, Paul F. Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series. Neurol Neuroimmunol Neuroinflamm. 2026 Mar; 13(2):e200548.
Score: 0.227
-
Pittock SJ, Barnett M, Bennett JL, Berthele A, de Sèze J, Levy M, Nakashima I, Oreja-Guevara C, Palace J, Paul F, Pozzilli C, Yountz M, Allen K, Mashhoon Y, Kim HJ. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. Ann Neurol. 2023 06; 93(6):1053-1068.
Score: 0.047
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|